Voyager Therapeutics Inc Investor Relations Material

Voyager Therapeutics, Inc. is a gene therapy company focused on the development of treatments and next-generation platform technologies. The company’s lead clinical candidate is VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy and frontotemporal dementia as well as for spinal muscular atrophy.